#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Janet Freeman-Daily @JFreemanDaily Welcome to #LCSM Chat! Tonight we will be discussing the much-anticipated “#ASCO20 Roundup for #LungCancer.” More info on our blog at https://t.co/KtLNwbe11K |
 | Faces of Lung Cancer @LungCancerFaces I’ll be tweeting from the @lcsmchat account tonight during #LCSM Chat starting right now. Join me! |
 | #LCSM Chat @lcsmchat RT @JFreemanDaily: Welcome to #LCSM Chat! Tonight we will be discussing the much-anticipated “#ASCO20 Roundup for #LungCancer.” More info on our blog at https://t.co/KtLNwbe11K |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Welcome to #LCSM Chat! Tonight we will be discussing the much-anticipated “#ASCO20 Roundup for #LungCancer.” More info on our blog at https://t.co/KtLNwbe11K |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: I’ll be tweeting from the @lcsmchat account tonight during #LCSM Chat starting right now. Join me! |
| Janet Freeman-Daily @JFreemanDaily We'll get started in a few minutes -- please take a moment to introduce yourselves #LCSM |
 | KC Dill @kasedill Hello from Houston KC checking in. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: We'll get started in a few minutes -- please take a moment to introduce yourselves #LCSM |
 | Charu Aggarwal, MD, MPH @CharuAggarwalMD Excited to join in on #LCSM chat tonight. I am a medical oncologist @PennCancer. Excited to discuss #ASCO20 |
| Janet Freeman-Daily @JFreemanDaily I’m your moderator Janet Freeman-Daily (writer, science geek, #lungcancer patient/research advocate). #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tim here. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We'll get started in a few minutes -- please take a moment to introduce yourselves #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: I’m your moderator Janet Freeman-Daily (writer, science geek, #lungcancer patient/research advocate). #LCSM |
 | Eric Bernicker @EricBernicker Hello! Medical oncologist and friend to pathologists here from Houston Texas #LCSM |
 | Henning Willers, MD (he/him/his) @HenningWillers Good evening, #lungcancer #radonc #physicianscientist @MGHCancerCenter @MGHThoracicOnc. Normally do not attend @ASCO Meeting but it was easier this year! #lcsm |
 | Jill Feldman @jillfeldman4 Hi All, Jill here #LCSM |
| #LCSM Chat @lcsmchat @CharuAggarwalMD @PennCancer Nice to see you tonight! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: I’m your moderator Janet Freeman-Daily (writer, science geek, #lungcancer patient/research advocate). #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @JFreemanDaily Looking forward to a great discussion! #LCSM |
 | Lisa Briggs @livinglife82 Hello from Down Under 🇦🇺 #LCSM |
| #LCSM Chat @lcsmchat @EricBernicker Welcome Doctor! #lcsm |
 | Arpan Patel @ArpanAshokPatel Arpan here from @WilmotCancer. |
| Janet Freeman-Daily @JFreemanDaily Hey Tim & Charu! Also a hat tip to my trusty sidekick @LungCancerFaces (Deana Hendrickson) #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Howdy Eric! #LCSM |
 | Joni Fowler, PharmD, BCPP @jfowlerpharmd @JFreemanDaily @lcsmchat Joni Fowler. Exhausted pharmacist and Zoom protege! #lcsm |
 | kristen kimball @KimballKristen Kris sitting in from my Boston porch, hello! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Hey Tim & Charu! Also a hat tip to my trusty sidekick @LungCancerFaces (Deana Hendrickson) #LCSM |
| #LCSM Chat @lcsmchat @livinglife82 Hello Lisa! #lcsm |
 | Kristin Ito @KAdvocate_LCAM Hi team! Kristin Ito with the IASLC, from Denver, CO here. With everything going on, I hope all are finding light and love in the little moments of each day. #lcsm |
 | semdogan @semdogan RT @APassaroMD: 💥 #ASCO20 #LCSM ADAURA Clear improvement of DFS in favour OSI but many open questions are emerged. DFS was highly significant, of course potentially practice changing but... Would you feel safe to use Osi in adjuvant thinking about your patients/OS? https://t.co/ZqKM5ZItC2 |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Hey Tim & Charu! Also a hat tip to my trusty sidekick @LungCancerFaces (Deana Hendrickson) #LCSM |
 | Matthew Katz, MD 🇺🇸 💜 @subatomicdoc Good evening! Matt Katz, radiation oncologist in MA/NH #lcsm |
| #LCSM Chat @lcsmchat @jfowlerpharmd @JFreemanDaily Welcome, Joni! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hi Arpan and Joni! Glad you joined us. #LCSM |
 | Dave Bjork @bjork5 @JFreemanDaily Hey Janet, Dave here from Boston #LCSM |
| Janet Freeman-Daily @JFreemanDaily If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb #LCSM |
 | Devika Das, MD, MSHQS @DevikaDasMD @JFreemanDaily @lcsmchat Hi Devika Das here - academic thoracic oncologists from Alabam #lcsm mostly listening and learning :) |
| #LCSM Chat @lcsmchat @KimballKristen Hi Kris! Thank for joining. #lcsm |
 | H. Jack West, MD @JackWestMD Hi, Jack West, med onc w/lung cancer focus, in LA at @CityofHope Excited to have lots to discuss. #lcsm |
| #LCSM Chat @lcsmchat @KAdvocate_LCAM What a lovely thought, Kristin. #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hi Dave, Matt, Kristin and Kristen! #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @HenningWillers All the #lcsm chats are great, I do my best to make them when I can! How are you? |
| #LCSM Chat @lcsmchat @subatomicdoc Hey Matt! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb #LCSM |
 | Dr. Amy C. Moore @acmoorephd Hi, everyone. This is Amy Moore, Director of Science & Research @GO2Foundation. #lcsm |
| Janet Freeman-Daily @JFreemanDaily Please remember to use #lcsm in all your tweets so others participating in the chat can see them. If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience. #LCSM |
| #LCSM Chat @lcsmchat @DevikaDasMD @JFreemanDaily Welcome! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Howdy Matt! #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers @subatomicdoc just here to listen to @JackWestMD and learn I guess :-) #lcsm |
| #LCSM Chat @lcsmchat @JackWestMD @cityofhope Hi Jack!!!! #lcsm |
 | Peggy Dennis @peggyddennis #lcsm Hi All. Peggy joining in from Denver |
| Dr. Amy C. Moore @acmoorephd Join us for a recap of #ASCO20 #lcsm |
| #LCSM Chat @lcsmchat @acmoorephd @GO2Foundation Hi Dr Moore! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hi Devika, Jack, and Henning. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Please remember to use #lcsm in all your tweets so others participating in the chat can see them. If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience. #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @TimAllenMDJD Hi Tim! #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @HenningWillers @JackWestMD me too! #lcsm |
| Kristin Ito @KAdvocate_LCAM RT @JFreemanDaily: Please remember to use #lcsm in all your tweets so others participating in the chat can see them. If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience. #LCSM |
| #LCSM Chat @lcsmchat @peggyddennis Welcome Peggy #lcsm |
| H. Jack West, MD @JackWestMD Hey. Sorry to be a stranger. This time competes with a standing meeting for me now. RT @lcsmchat: @JackWestMD @cityofhope Hi Jack!!!! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @JackWestMD tried to find your list of top #ASCO20 abstracts with no luck. The one Link I found was broken. Are you neglecting your habits? #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @JackWestMD tried to find your list of top #ASCO20 abstracts with no luck. The one Link I found was broken. Are you neglecting your habits? #LCSM |
| Janet Freeman-Daily @JFreemanDaily Note: Twitter allows tweets up to 280 characters, but some tweetchat apps (like https://t.co/A2M7gXQ66L) will not display tweets longer than 140. #LCSM |
| Janet Freeman-Daily @JFreemanDaily I will announce FOUR topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #LCSM |
| Janet Freeman-Daily @JFreemanDaily We’ll start with Topic T1 in a minute … #LCSM |
| Dr. Amy C. Moore @acmoorephd Here is @GO2Foundation's ASCO recap: https://t.co/JAiKkJVLGB #ASCO20 #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Note: Note: Twitter allows tweets up to 280 characters, but some tweetchat apps (like https://t.co/A2M7gXQ66L) will not display tweets longer than 140. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: I will announce FOUR topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #LCSM |
| Janet Freeman-Daily @JFreemanDaily T1. What information was presented at #ASCO20 about COVID-19 and cancer? #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We’ll start with Topic T1 in a minute … #LCSM |
| #LCSM Chat @lcsmchat RT @acmoorephd: Here is @GO2Foundation's ASCO recap: Here is @GO2Foundation's ASCO recap: https://t.co/JAiKkJVLGB #ASCO20 #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1. What information was presented at #ASCO20 about COVID-19 and cancer? #LCSM |
| Dr. Amy C. Moore @acmoorephd Pretty sure @JackWestMD broke ASCO on the first day ;) He jinxed it watching everything on superspeed #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @JFreemanDaily T1 I thought the #TERAVOLT presentation was really relevant to #LCSM. Link here: https://t.co/wf17m6hOZb |
 | Narjust Florez (Duma), M.D. @NarjustFlorezMD @HenningWillers @subatomicdoc @JackWestMD Same here, learning from Master Jedi Jack. #lcsm Narjust Duma, MD Thoracic oncology at @UWMadison |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @JFreemanDaily T1 I thought the #TERAVOLT presentation was really relevant to #LCSM. Link here: @JFreemanDaily T1 I thought the #TERAVOLT presentation was really relevant to #LCSM. Link here: https://t.co/wf17m6hOZb |
| Janet Freeman-Daily @JFreemanDaily Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) (Abs LBA110) #ASCO20 #lcsm https://t.co/t5gL7uphid https://t.co/oGCknRMahw |
| Henning Willers, MD (he/him/his) @HenningWillers RT @JFreemanDaily: Clinical impact of COVID-19 on patients with cancer: Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) (Abs LBA110) #ASCO20 #lcsm https://t.co/t5gL7uphid https://t.co/oGCknRMahw |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Clinical impact of COVID-19 on patients with cancer: Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) (Abs LBA110) #ASCO20 #lcsm https://t.co/t5gL7uphid https://t.co/oGCknRMahw |
 | CTSurgSocMedNetwork @tssmn RT @lcsmchat: TODAY! Join #LCSM Chat Thursday 6/4 at 5pm PT, 8pm ET for our #ASCO20 Roundup for Lung Cancer. Read more here: TODAY! Join #LCSM Chat Thursday 6/4 at 5pm PT, 8pm ET for our #ASCO20 Roundup for Lung Cancer. Read more here: https://t.co/Vlu8vdiGyw Please spread the word! @drCarterHarris @TommyJohn00 @DrewMoghanaki @Jbauml @OtisBRickman @ChristianRolfo @SBRT_CR @jmeberth #hcsm #meded #tssmn https://t.co/sd43RpXGGq |
| Henning Willers, MD (he/him/his) @HenningWillers RT @CharuAggarwalMD: @JFreemanDaily T1 I thought the #TERAVOLT presentation was really relevant to #LCSM. Link here: @JFreemanDaily T1 I thought the #TERAVOLT presentation was really relevant to #LCSM. Link here: https://t.co/wf17m6hOZb |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @CharuAggarwalMD @JFreemanDaily I agree with Charu, the virus is going to be around for a while and learning from their experience is invaluable. #LCSM |
| H. Jack West, MD @JackWestMD RT @acmoorephd: Pretty sure @JackWestMD broke ASCO on the first day ;) He jinxed it watching everything on superspeed #lcsm |
| Janet Freeman-Daily @JFreemanDaily @CharuAggarwalMD TERAVOLT was definitely relevant to #LCSM! thanks for sharing |
 | Sabin Motwani @sabinbmotwanimd @JFreemanDaily paper published in @TheLancet https://t.co/JoQxRcebhX #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @acmoorephd: Pretty sure @JackWestMD broke ASCO on the first day ;) He jinxed it watching everything on superspeed #lcsm |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @CharuAggarwalMD @JFreemanDaily I agree with Charu, the virus is going to be around for a while and learning from their experience is invaluable. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @acmoorephd: Here is @GO2Foundation's ASCO recap: Here is @GO2Foundation's ASCO recap: https://t.co/JAiKkJVLGB #ASCO20 #lcsm |
| Arpan Patel @ArpanAshokPatel RT @CharuAggarwalMD: @JFreemanDaily T1 I thought the #TERAVOLT presentation was really relevant to #LCSM. Link here: @JFreemanDaily T1 I thought the #TERAVOLT presentation was really relevant to #LCSM. Link here: https://t.co/wf17m6hOZb |
 | Laronica Conway @louisianagirl91 Hey everyone! Laronica, lung cancer advocate & #radonc research coordinator in Birmingham! I MISS my #LCSM peeps! I’m here, but not really. Didn’t get a chance to keep up w #ASCO20 this year so I’ll be “lurking”. Just wanted to say HEEEYYYYY!! 💕 #lcsm |
| #LCSM Chat @lcsmchat RT @sabinbmotwanimd: @JFreemanDaily paper published in @TheLancet https://t.co/JoQxRcebhX #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD Age, performance status and comorbidity seem to be big risk factors for #COVID19 #LCSM https://t.co/x8y7wNmrvn |
| Jill Feldman @jillfeldman4 Yes, and I hope this global collaboration continues! It's amazing what can be done when we work together #LCSM |
| Eric Bernicker @EricBernicker Patients with progressive lung cancer did especially poorly with this virus; honest discussions with patients and families need to be had #LCMS |
| Dave Bjork @bjork5 Thanks for sharing #lcsm |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @JFreemanDaily A1: We also learned from the COVID-19 and Cancer Consortium lead by @hemoncwarner and @ADesaiMD Very important data as we continue to learn about the virus in our patients with cancer. #LCSM |
 | Jo Taylor @abcdiagnosis RT @AmazzoneFuriosa: My dear friend @Cinzia_Greco_ is working on a Wellcome Trust project comparing the experiences of people diagnosed w/ breast & lung cancer in different countries, including the UK. If you're willing to talk to her, please get in touch #bcsm #bccww #lcsm https://t.co/0CXJqVYEpr https://t.co/epJaAFfE9L |
| Dr. Amy C. Moore @acmoorephd T1: #TERAVOLT and @COVID19nCCC showed increasing evidence to support worse outcomes for cancer patients, with #COVID19 presenting a real threat for #lungcancer patients, especially those with active cancer and on chemo #lcsm |
| #LCSM Chat @lcsmchat @louisianagirl91 Hey Roni! #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Age, performance status and comorbidity seem to be big risk factors for #COVID19 #LCSM https://t.co/x8y7wNmrvn |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @louisianagirl91 Hola! #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: Yes, and I hope this global collaboration continues! It's amazing what can be done when we work together #LCSM |
 | Edward Bender, MD @ebender001 RT tssmn "RT lcsmchat: TODAY! Join #LCSM Chat Thursday 6/4 at 5pm PT, 8pm ET for our #ASCO20 Roundup for Lung Cancer. Read more here: https://t.co/ogSIscpfLs Please spread the word! drCarterHarris TommyJohn00 DrewMoghanaki Jbauml OtisBRickman ChristianR… https://t.co/LrVWxQcy9r" |
| Lisa Briggs @livinglife82 RT @JFreemanDaily: Clinical impact of COVID-19 on patients with cancer: Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) (Abs LBA110) #ASCO20 #lcsm https://t.co/t5gL7uphid https://t.co/oGCknRMahw |
| Sabin Motwani @sabinbmotwanimd A1. Not sure if presented at #ASCO20 but this was also published in same @TheLancet edition as CCC19 https://t.co/o5U1OUDOce #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @NarjustDumaMD @JFreemanDaily @hemoncwarner @ADesaiMD Amazing how quickly this data came together. Very timely presentation #LCSM |
| Janet Freeman-Daily @JFreemanDaily Loved this #ASCO20 discussant presentation Looking Back on COVID in order to Move Forward (discussant) https://t.co/4ewVUbyI2H #LCSM https://t.co/YdpnvkDRH4 |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @JFreemanDaily A1: @JFreemanDaily A1: We also learned from the COVID-19 and Cancer Consortium lead by @hemoncwarner and @ADesaiMD Very important data as we continue to learn about the virus in our patients with cancer. #LCSM |
| Dave Bjork @bjork5 @louisianagirl91 Heeey! #lcsm 😊 |
| #LCSM Chat @lcsmchat RT @acmoorephd: T1: T1: #TERAVOLT and @COVID19nCCC showed increasing evidence to support worse outcomes for cancer patients, with #COVID19 presenting a real threat for #lungcancer patients, especially those with active cancer and on chemo #lcsm |
| Laronica Conway @louisianagirl91 @lcsmchat 💕💕💕 #lcsm https://t.co/X6sdGn2IJg |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @acmoorephd @COVID19nCCC And worse outcomes in those with poor PS #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers RT @JFreemanDaily: Loved this #ASCO20 discussant presentation Looking Back on COVID in order to Move Forward (discussant) https://t.co/4ewVUbyI2H #LCSM https://t.co/YdpnvkDRH4 |
| #LCSM Chat @lcsmchat RT @sabinbmotwanimd: A1. Not sure if presented at #ASCO20 but this was also published in same @TheLancet edition as CCC19 https://t.co/o5U1OUDOce #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @CharuAggarwalMD: Age, performance status and comorbidity seem to be big risk factors for #COVID19 #LCSM https://t.co/x8y7wNmrvn |
| Arpan Patel @ArpanAshokPatel RT @JFreemanDaily: Loved this #ASCO20 discussant presentation Looking Back on COVID in order to Move Forward (discussant) https://t.co/4ewVUbyI2H #LCSM https://t.co/YdpnvkDRH4 |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Loved this #ASCO20 discussant presentation Looking Back on COVID in order to Move Forward (discussant) https://t.co/4ewVUbyI2H #LCSM https://t.co/YdpnvkDRH4 |
| Dr. Amy C. Moore @acmoorephd Yes, excellent presentation |
| H. Jack West, MD @JackWestMD @CharuAggarwalMD @JFreemanDaily Agree. I think the take-home message was higher risk of COVID-19 complications & deaths in pts w/LC. Reminds us we should be vy cautious about exposures. #LCSM |
| Janet Freeman-Daily @JFreemanDaily Dr. Sharpless also had some good comments Ensuring Cancer Research Progress During a Global Pandemic https://t.co/TlVMEqf0z5 #ASCO20 #LCSM https://t.co/vHVLKsYBGr |
| #LCSM Chat @lcsmchat RT @JackWestMD: @CharuAggarwalMD @JFreemanDaily Agree. I think the take-home message was higher risk of COVID-19 complications & deaths in pts w/LC. Reminds us we should be vy cautious about exposures. #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @JFreemanDaily @curijoey was amazing #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Dr. Sharpless also had some good comments Ensuring Cancer Research Progress During a Global Pandemic https://t.co/TlVMEqf0z5 #ASCO20 #LCSM https://t.co/vHVLKsYBGr |
| H. Jack West, MD @JackWestMD RT @JFreemanDaily: Loved this #ASCO20 discussant presentation Looking Back on COVID in order to Move Forward (discussant) https://t.co/4ewVUbyI2H #LCSM https://t.co/YdpnvkDRH4 |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @JFreemanDaily: Dr. Sharpless also had some good comments Ensuring Cancer Research Progress During a Global Pandemic https://t.co/TlVMEqf0z5 #ASCO20 #LCSM https://t.co/vHVLKsYBGr |
| Eric Bernicker @EricBernicker @CharuAggarwalMD @acmoorephd @COVID19nCCC Obviously not a surprise but makes discussion of second line cytotoxic chemotherapy in an elderly patient a very important one #LCSM |
| Dr. Amy C. Moore @acmoorephd RT @JackWestMD: @CharuAggarwalMD @JFreemanDaily Agree. I think the take-home message was higher risk of COVID-19 complications & deaths in pts w/LC. Reminds us we should be vy cautious about exposures. #LCSM |
 | Vamsi Velcheti, MD @VamsiVelcheti Vamsi Velcheti joining #LCSM @nyulangone #lcsmchat |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @EricBernicker: @CharuAggarwalMD @acmoorephd @COVID19nCCC Obviously not a surprise but makes discussion of second line cytotoxic chemotherapy in an elderly patient a very important one #LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: @CharuAggarwalMD @acmoorephd @COVID19nCCC Obviously not a surprise but makes discussion of second line cytotoxic chemotherapy in an elderly patient a very important one #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @EricBernicker @acmoorephd @COVID19nCCC We have had more goal oriented talks, for sure #LCSM |
| Dr. Amy C. Moore @acmoorephd How can the #lungcancer advocacy community continue to carry this message forward to protect patients? #lcsm |
| Kristin Ito @KAdvocate_LCAM T1: @GO2Foundation crafted a nice & easy to read summary of some major outcomes of ASCO. #LCSM There is a section related to COVID and cancer. |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @JFreemanDaily He also has a great round table with @OncoAlert where he shared his experience during the surge in Italy. #LCSM https://t.co/MmglA9hQye |
 | Tom Varghese Jr. MD, MS, MBA, FACS 🇺🇸 @TomVargheseJr RT @JFreemanDaily: Clinical impact of COVID-19 on patients with cancer: Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) (Abs LBA110) #ASCO20 #lcsm https://t.co/t5gL7uphid https://t.co/oGCknRMahw |
| Arpan Patel @ArpanAshokPatel @JackWestMD @CharuAggarwalMD @JFreemanDaily And to do everything we can to make sure our patients with lung cancer don’t get #covid19 #socialdistancing #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers RT @NarjustDumaMD: @JFreemanDaily He also has a great round table with @OncoAlert where he shared his experience during the surge in Italy. #LCSM https://t.co/MmglA9hQye |
| #LCSM Chat @lcsmchat RT @acmoorephd: How can the #lungcancer advocacy community continue to carry this message forward to protect patients? #lcsm |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: T1: T1: @GO2Foundation crafted a nice & easy to read summary of some major outcomes of ASCO. #LCSM There is a section related to COVID and cancer. |
| Janet Freeman-Daily @JFreemanDaily Topic T2 is coming up … (that's the meaty stuff: #ASCO2- #lungcancer abstracts!) #LCSM |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @JFreemanDaily He also has a great round table with @OncoAlert where he shared his experience during the surge in Italy. #LCSM https://t.co/MmglA9hQye |
| #LCSM Chat @lcsmchat RT @ArpanAshokPatel: @JackWestMD @CharuAggarwalMD @JFreemanDaily And to do everything we can to make sure our patients with lung cancer don’t get #covid19 #socialdistancing #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Topic T2 is coming up … (that's the meaty stuff: Topic T2 is coming up … (that's the meaty stuff: #ASCO2- #lungcancer abstracts!) #LCSM |
| Tom Varghese Jr. MD, MS, MBA, FACS 🇺🇸 @TomVargheseJr RT @jillfeldman4: Yes, and I hope this global collaboration continues! It's amazing what can be done when we work together #LCSM |
 | Matthew Smeltzer @MattSmeltzer Good evening everyone! #LCSM |
| Janet Freeman-Daily @JFreemanDaily T2. What were the top abstracts at #ASCO20 specifically about lung cancer (screening, diagnosis, treatment, care)?#LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2. What were the top abstracts at #ASCO20 specifically about lung cancer (screening, diagnosis, treatment, care)?#LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @EricBernicker @acmoorephd @COVID19nCCC From #TERAVOLT #ASCO20 #LCSM https://t.co/lxwmHbJxhy |
| Lisa Briggs @livinglife82 @NarjustDumaMD @JFreemanDaily @OncoAlert I’ll have to watch this! Haven’t seen it so thanks for sharing #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @EricBernicker @acmoorephd @COVID19nCCC From #TERAVOLT #ASCO20 #LCSM https://t.co/lxwmHbJxhy |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T2. What were the top abstracts at #ASCO20 specifically about lung cancer (screening, diagnosis, treatment, care)?#LCSM |
| Vamsi Velcheti, MD @VamsiVelcheti @CharuAggarwalMD @JFreemanDaily It is important to create a #COVID19 safe environment for our patients #LCSM #SocialDistancing #Masks4All |
 | Lillian Leigh @ProjectBreath RT @JFreemanDaily: Dr. Sharpless also had some good comments Ensuring Cancer Research Progress During a Global Pandemic https://t.co/TlVMEqf0z5 #ASCO20 #LCSM https://t.co/vHVLKsYBGr |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @JFreemanDaily This was my list going into #ASCO20 #LCSM https://t.co/pjXjAhIFm5 |
| #LCSM Chat @lcsmchat RT @VamsiVelcheti: @CharuAggarwalMD @JFreemanDaily It is important to create a #COVID19 safe environment for our patients #LCSM #SocialDistancing #Masks4All |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @JFreemanDaily This was my list going into #ASCO20 #LCSM https://t.co/pjXjAhIFm5 |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @JFreemanDaily A2: I will say ADAURA Trial. #LCSM |
| Lisa Briggs @livinglife82 @JFreemanDaily I could not agree more with the #research priorities listed on page 2 #LCSM |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @JFreemanDaily A2: @JFreemanDaily A2: I will say ADAURA Trial. #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD Lot of data on #TargetedTherapy, making #NGS an absolute necessity! MET, HER2 being a few examples #LCSM #ASCO20 |
| Janet Freeman-Daily @JFreemanDaily These #lungcancer #ASCO20 seem to be on most of the top 10 lists #LCSM https://t.co/70a8ZEGFAm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @JFreemanDaily: T2. What were the top abstracts at #ASCO20 specifically about lung cancer (screening, diagnosis, treatment, care)?#LCSM |
| Arpan Patel @ArpanAshokPatel #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Lot of data on #TargetedTherapy, making #NGS an absolute necessity! MET, HER2 being a few examples #LCSM #ASCO20 |
| Lillian Leigh @ProjectBreath RT @JFreemanDaily: These #lungcancer #ASCO20 seem to be on most of the top 10 lists #LCSM https://t.co/70a8ZEGFAm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: These #lungcancer #ASCO20 seem to be on most of the top 10 lists #LCSM https://t.co/70a8ZEGFAm |
| H. Jack West, MD @JackWestMD T2: #ADAURA trial, by a wide margin, was highest interest & impact. Unquestionably a pos trial for post-op Tagrisso (osimertinib) in pts w/resected EGFRm+ NSCLC. Key Q is if that means much w/o showing more pts living longer, & whether we should care about societal costs. #LCSM |
| Dr. Amy C. Moore @acmoorephd A2: For sure the most anticipated was ADAURA #lcsm |
| #LCSM Chat @lcsmchat RT @ArpanAshokPatel: #LCSM |
| Devika Das, MD, MSHQS @DevikaDasMD @acmoorephd Masking, good hygiene practices in infusion rooms and clinic visits, not withholding life prolonging therapy and mostly for rest of the community to do all they can to protect vulnerable patients with #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Lot of data on #TargetedTherapy, making #NGS an absolute necessity! MET, HER2 being a few examples #LCSM #ASCO20 |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD This, of course created a lot of debate #LCSM #ASCO20 |
| Vamsi Velcheti, MD @VamsiVelcheti we have started testing all employees and patients @nyulangone with both PCR and Ab #COVIDー19 and strict #SocialDistanacing #LCSM #lcsmchat |
| Janet Freeman-Daily @JFreemanDaily @CharuAggarwalMD Now we just have to get that "reflex NGS testing for NSCLC" piece in place for all #lungcancer and #cancer clinics! #LCSM |
| Sabin Motwani @sabinbmotwanimd A2: ADAURA trial was a plenary talk #LCSM which looked at osimertinib as adj therapy in Stage I-IIIA mNSCLC after complete resection https://t.co/DY05438ibP #LCSM |
| #LCSM Chat @lcsmchat RT @DevikaDasMD: @acmoorephd Masking, good hygiene practices in infusion rooms and clinic visits, not withholding life prolonging therapy and mostly for rest of the community to do all they can to protect vulnerable patients with #lcsm |
| Kristin Ito @KAdvocate_LCAM RT @JFreemanDaily: These #lungcancer #ASCO20 seem to be on most of the top 10 lists #LCSM https://t.co/70a8ZEGFAm |
| #LCSM Chat @lcsmchat RT @acmoorephd: A2: A2: For sure the most anticipated was ADAURA #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: T2: T2: #ADAURA trial, by a wide margin, was highest interest & impact. Unquestionably a pos trial for post-op Tagrisso (osimertinib) in pts w/resected EGFRm+ NSCLC. Key Q is if that means much w/o showing more pts living longer, & whether we should care about societal costs. #LCSM |
| #LCSM Chat @lcsmchat RT @VamsiVelcheti: we have started testing all employees and patients @nyulangone with both PCR and Ab #COVIDー19 and strict #SocialDistanacing #LCSM #lcsmchat |
| Dr. Amy C. Moore @acmoorephd RT @JFreemanDaily: These #lungcancer #ASCO20 seem to be on most of the top 10 lists #LCSM https://t.co/70a8ZEGFAm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @CharuAggarwalMD Now we just have to get that "reflex NGS testing for NSCLC" piece in place for all #lungcancer and #cancer clinics! #LCSM |
| #LCSM Chat @lcsmchat RT @sabinbmotwanimd: A2: A2: ADAURA trial was a plenary talk #LCSM which looked at osimertinib as adj therapy in Stage I-IIIA mNSCLC after complete resection https://t.co/DY05438ibP #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @JFreemanDaily Easier said than done. Very hard to implement, but we MUST do it #NGS #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers A2 - finding optimal dose fractionation for #radiotherapy in LS-SCLC remains an unmet need #ASCO20 #lcsm https://t.co/S0tjMENOnz |
| Jill Feldman @jillfeldman4 T1 We do need to be safe, but as society opens up it's hard for us/patients to watch others re-enter (like going to rally's) & wanting to do the same. Being 'safe' is tough for many #LCSM |
| Janet Freeman-Daily @JFreemanDaily Interesting to see results of a new ICI checkpoint CITYSCAPE – first line anti-TIGIT antibody tiragolumab+atezo vs placebo+atezo in PD-L1-selected stg 3/4 NSCLC (Abs 9503) https://t.co/D7C89yrnei #LCSM #ASCO20 https://t.co/bbXJbrz0di |
| #LCSM Chat @lcsmchat RT @HenningWillers: A2 - finding optimal dose fractionation for #radiotherapy in LS-SCLC remains an unmet need #ASCO20 #lcsm https://t.co/S0tjMENOnz |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @JFreemanDaily A2. Possible markers to determine if radiation may not work in certain NSCLC tumors #lcsm #radonc KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. https://t.co/yRL9kQHK1f |
| H. Jack West, MD @JackWestMD T2: We saw data on interesting alternative immunotherapy options, most notably Opdivo (nivolumab) w/Yervoy (ipilimumab), either w/no chemo (Checkmate 227) or w/2 cycles of chemo up from (Checkmate-9LA). Results were fine, but not better than what we have already. #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T1 We do need to be safe, but as society opens up it's hard for us/patients to watch others re-enter (like going to rally's) & wanting to do the same. Being 'safe' is tough for many #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Interesting to see results of a new ICI checkpoint CITYSCAPE – first line anti-TIGIT antibody tiragolumab+atezo vs placebo+atezo in PD-L1-selected stg 3/4 NSCLC (Abs 9503) https://t.co/D7C89yrnei #LCSM #ASCO20 https://t.co/bbXJbrz0di |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @JFreemanDaily A2. Possible markers to determine if radiation may not work in certain NSCLC tumors #lcsm #radonc KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. https://t.co/yRL9kQHK1f |
| #LCSM Chat @lcsmchat RT @JackWestMD: T2: T2: We saw data on interesting alternative immunotherapy options, most notably Opdivo (nivolumab) w/Yervoy (ipilimumab), either w/no chemo (Checkmate 227) or w/2 cycles of chemo up from (Checkmate-9LA). Results were fine, but not better than what we have already. #LCSM |
| Arpan Patel @ArpanAshokPatel #LCSM IO therapy 2.0! |
| Dr. Amy C. Moore @acmoorephd RT @JackWestMD: T2: T2: #ADAURA trial, by a wide margin, was highest interest & impact. Unquestionably a pos trial for post-op Tagrisso (osimertinib) in pts w/resected EGFRm+ NSCLC. Key Q is if that means much w/o showing more pts living longer, & whether we should care about societal costs. #LCSM |
| Eric Bernicker @EricBernicker It has been an imperative for years, even before the MET and RET data. #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD Very interesting study, but underwhelming activity in the 1-49% category, very impressive in PDL-1 high, and warrants further study #LCSM |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @JackWestMD A2: The challenges about these studies are the comparisons with old standard of care. #LCSM |
 | Isaac Kohane @zakkohane Planning @theNCI to avoid future lives lost due to cancer research slowed + trials interrupted by COVID19 recalls tradeoff that became apparent on March 23 about current vs future patients https://t.co/D5xCXKWJlo |
| H. Jack West, MD @JackWestMD T2: Agree this was most important result in small cell. Otherwise, several trials presented immunotherapy + chemo, but really just replicating what we already have with trials (& FDA approvals) w/Tecentriq (atezolizumab) or Imfinzi (durvalumab) + chemo. #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @EricBernicker Yes, but becomes even more relevant with each meeting #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @JFreemanDaily A2. Breast cancer has defined, different diseases by molecular subtypes. Is small cell lung cancer next? #lcsm https://t.co/NljxC1EaLe Molecular subtypes and clinical outcomes to initial systemic treatment in patients with small cell lung cancer. |
| Janet Freeman-Daily @JFreemanDaily Somewhat concerned about toxicities of nivo-ipi-chemo combos. The number and severity of potential side effects may require patient to stay near the hospital during treatment. #LCSM |
 | Gloria Minott @gloriaminott RT @TestLungCancer: After his mom’s diagnosis, PGA golf champion Jason Day was given a lot of advice about how to help her through Stage IV non-small cell #lungcancer diagnosis. Here is what he learned about finding the right treatment options. #LCSM |
| Jill Feldman @jillfeldman4 RT @subatomicdoc: @JFreemanDaily A2. Possible markers to determine if radiation may not work in certain NSCLC tumors #lcsm #radonc KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. https://t.co/yRL9kQHK1f |
| #LCSM Chat @lcsmchat RT @ArpanAshokPatel: #LCSM IO therapy 2.0! |
| #LCSM Chat @lcsmchat RT @EricBernicker: It has been an imperative for years, even before the MET and RET data. #LCSM |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @subatomicdoc @JFreemanDaily What are your thoughts about the data with SBRT and patients with EGFR positive lung cancer? #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Very interesting study, but underwhelming activity in the 1-49% category, very impressive in PDL-1 high, and warrants further study #LCSM |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @JackWestMD A2: @JackWestMD A2: The challenges about these studies are the comparisons with old standard of care. #LCSM |
| #LCSM Chat @lcsmchat RT @JackWestMD: T2: T2: Agree this was most important result in small cell. Otherwise, several trials presented immunotherapy + chemo, but really just replicating what we already have with trials (& FDA approvals) w/Tecentriq (atezolizumab) or Imfinzi (durvalumab) + chemo. #LCSM |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @JFreemanDaily A2. Breast cancer has defined, different diseases by molecular subtypes. Is small cell lung cancer next? #lcsm https://t.co/NljxC1EaLe Molecular subtypes and clinical outcomes to initial systemic treatment in patients with small cell lung cancer. |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Somewhat concerned about toxicities of nivo-ipi-chemo combos. The number and severity of potential side effects may require patient to stay near the hospital during treatment. #LCSM |
| Eric Bernicker @EricBernicker So important to work on developing negative as well as positive predictive biomarkers. The latter tend to get all of the love #LCSM |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @subatomicdoc @JFreemanDaily What are your thoughts about the data with SBRT and patients with EGFR positive lung cancer? #LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: So important to work on developing negative as well as positive predictive biomarkers. The latter tend to get all of the love #LCSM |
 | COSA @COSAoncology RT @Lungfoundation: Join #ALTG leading clinicians to discuss & debate #ASCO2020 highlights & impact on thoracic oncology practice. Registration is required to attend the live webinar or view the recording https://t.co/iA2M67bXCl #ALTGonASCO20 #LCSM See more on ALTG https://t.co/GShR1XKdpK https://t.co/VUdNHMqlQy |
 | Dr. Jan Marie Eberth @jmeberth RT @lcsmchat: TODAY! Join #LCSM Chat Thursday 6/4 at 5pm PT, 8pm ET for our #ASCO20 Roundup for Lung Cancer. Read more here: TODAY! Join #LCSM Chat Thursday 6/4 at 5pm PT, 8pm ET for our #ASCO20 Roundup for Lung Cancer. Read more here: https://t.co/Vlu8vdiGyw Please spread the word! @drCarterHarris @TommyJohn00 @DrewMoghanaki @Jbauml @OtisBRickman @ChristianRolfo @SBRT_CR @jmeberth #hcsm #meded #tssmn https://t.co/sd43RpXGGq |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @NarjustDumaMD @JFreemanDaily I missed that, was there an abstract on it? I'd defer to experts like @HenningWillers but happy to look at it! Thanks! #lcsm |
 | Mersiha Hadziahmetovic MD @MHadziMD RT @JackWestMD: I'd long considered SCLC a setting in which whole brain radiation therapy (WBRT) is categorically more appropriate than stereotactic radiosurg (SRS), but retrospective study challenges that assumption. Worth a read. https://t.co/AaevvfwFzb #LCSM #RadOnc @JAMAOnc #BTSM https://t.co/H1dZxZmIpN |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @CharuAggarwalMD @JFreemanDaily It needs to happen, NGS needs to become imperative. Like echocardiogram before anthracyclines. #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @NarjustDumaMD @JFreemanDaily I think we are slowly getting there #LCSM |
| Eric Bernicker @EricBernicker And seemingly impossible for many more :( |
| H. Jack West, MD @JackWestMD @JFreemanDaily Fair point. I think many of us wince when someone says "chemo-free" as if to mean "toxicity-free". Nivo/ipi +/- chemo isn't less toxic than any of our other regimens; overall similar intensity of side effects, but I'd say more unpredictable side effects than other combos. #LCSM |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @CharuAggarwalMD @JFreemanDaily It needs to happen, NGS needs to become imperative. Like echocardiogram before anthracyclines. #LCSM |
| #LCSM Chat @lcsmchat RT @JackWestMD: @JFreemanDaily Fair point. I think many of us wince when someone says "chemo-free" as if to mean "toxicity-free". Nivo/ipi +/- chemo isn't less toxic than any of our other regimens; overall similar intensity of side effects, but I'd say more unpredictable side effects than other combos. #LCSM |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @VamsiVelcheti @nyulangone Here at @UWMadison all physicians were given the option for Ab testing as well #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers @subatomicdoc @NarjustDumaMD @JFreemanDaily Upfront SBRT in #EGFR mut #lungcancer with first gen TKI, improved OS; confirms concept of cytoreduction to reduce risk of drug resistance (though we prefer consoidation SBRT) #LCSM |
| Dr. Jan Marie Eberth @jmeberth #LCSM Joining late but will try to catch up!! |
| Kristin Ito @KAdvocate_LCAM T2: Interesting to see that "ctDNA is highly concordant with tumor for MET..." Would this allow for less invasive testing? #stilllearning #lcsm From MET Mutations: The Meat of the Matter presentation https://t.co/w8Iiadk71z |
| Janet Freeman-Daily @JFreemanDaily So many interesting #EGFR abstracts at #ASCO20! @EGFRResistors had a great poster walkthrough session this afternoon. Congrats to @jillfeldman4 @ivybelkins @christine_lovly @LeciaSequist @Jbauml & CEC Oncology! #LCSM |
 | Brendon Stiles @BrendonStilesMD #lcsm Hi all! Sorry to be late! |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @HenningWillers: @subatomicdoc @NarjustDumaMD @JFreemanDaily Upfront SBRT in #EGFR mut #lungcancer with first gen TKI, improved OS; confirms concept of cytoreduction to reduce risk of drug resistance (though we prefer consoidation SBRT) #LCSM |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @CharuAggarwalMD Yes, it did. It still was the most "attractive" study in lung cancer #LCSM |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @VamsiVelcheti @nyulangone Here at @UWMadison all physicians were given the option for Ab testing as well #LCSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: @subatomicdoc @NarjustDumaMD @JFreemanDaily Upfront SBRT in #EGFR mut #lungcancer with first gen TKI, improved OS; confirms concept of cytoreduction to reduce risk of drug resistance (though we prefer consoidation SBRT) #LCSM |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: T2: T2: Interesting to see that "ctDNA is highly concordant with tumor for MET..." Would this allow for less invasive testing? #stilllearning #lcsm From MET Mutations: The Meat of the Matter presentation https://t.co/w8Iiadk71z |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: So many interesting #EGFR abstracts at #ASCO20! @EGFRResistors had a great poster walkthrough session this afternoon. Congrats to @jillfeldman4 @ivybelkins @christine_lovly @LeciaSequist @Jbauml & CEC Oncology! #LCSM |
| Jill Feldman @jillfeldman4 @JFreemanDaily @ivybelkins @christine_lovly @LeciaSequist @Jbauml Thank you! |
| Dr. Jan Marie Eberth @jmeberth RT @JackWestMD: @CharuAggarwalMD @JFreemanDaily Agree. I think the take-home message was higher risk of COVID-19 complications & deaths in pts w/LC. Reminds us we should be vy cautious about exposures. #LCSM |
| Brendon Stiles @BrendonStilesMD What did I miss? Other than all of you amazing people? Tough times, but always love seeing the #lcsm crowd. #lcsm |
| Jill Feldman @jillfeldman4 @NarjustDumaMD @subatomicdoc @JFreemanDaily T2 Effective systemic therapy + SBRT is promising. Question is when? Would upfront combat subclones? #LCSM |
 | Lung Cancer Sux @LungCancerSux Me too! |
| #LCSM Chat @lcsmchat RT @jillfeldman4: @NarjustDumaMD @subatomicdoc @JFreemanDaily T2 Effective systemic therapy + SBRT is promising. Question is when? Would upfront combat subclones? #LCSM |
| Janet Freeman-Daily @JFreemanDaily @subatomicdoc @NarjustDumaMD @HenningWillers SINDAS – first-line TKI (with upfront rads vs no rads) in oligometastatic EGFR NSCLC –up to 5 mets (Abs 9508) https://t.co/riZ3DQNJTp #ASCO20 #LCSM https://t.co/BRlCTa6OCR |
| Brendon Stiles @BrendonStilesMD @ProjectBreath Hi Lillian. Hope you are well! #lcsm |
| H. Jack West, MD @JackWestMD T2: want to also give a mention to impressive data w/new IV therapy Enhertu (trastuzumab deruxtecan), which targets HER2 effectively, looks like it should be targeted therapy we need for HER2 mut'n-pos NSCLC. Need more data, but I'm optimistic. #LCSM |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @MattSmeltzer @CharuAggarwalMD @JFreemanDaily Yes, cost is still a significant issues, for many groups particularly minorities and patients living in rural areas. It also worries me that many patients in Latin America will not have access to the drug, This, sadly, does not affect how impactful the study is. #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers @subatomicdoc @NarjustDumaMD @JFreemanDaily i am just gonna go adea and quote @JackWestMD again ... #LCSM https://t.co/hP9fBPdf6A |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @subatomicdoc @NarjustDumaMD @HenningWillers SINDAS – first-line TKI (with upfront rads vs no rads) in oligometastatic EGFR NSCLC –up to 5 mets (Abs 9508) https://t.co/riZ3DQNJTp #ASCO20 #LCSM https://t.co/BRlCTa6OCR |
 | Deb Smith 🌻 @debsmithbeach Deb in NH. #LCSM |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD RT @JFreemanDaily: @subatomicdoc @NarjustDumaMD @HenningWillers SINDAS – first-line TKI (with upfront rads vs no rads) in oligometastatic EGFR NSCLC –up to 5 mets (Abs 9508) https://t.co/riZ3DQNJTp #ASCO20 #LCSM https://t.co/BRlCTa6OCR |
| #LCSM Chat @lcsmchat RT @JackWestMD: T2: T2: want to also give a mention to impressive data w/new IV therapy Enhertu (trastuzumab deruxtecan), which targets HER2 effectively, looks like it should be targeted therapy we need for HER2 mut'n-pos NSCLC. Need more data, but I'm optimistic. #LCSM |
 | Unmasking the Reality of Lung Cancer @UnmaskingC RT @IASLC: Now available in the IASLC Lung Cancer News (ILCN): Now available in the IASLC Lung Cancer News (ILCN): @n8pennell discusses how it is time to end the debate on genomic testing in #NSCLC. #LCSM https://t.co/kNZh59V4cQ |
| Brendon Stiles @BrendonStilesMD Lots of big time lung cancer stars here tonight! #lcsm |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @MattSmeltzer @CharuAggarwalMD @JFreemanDaily Yes, cost is still a significant issues, for many groups particularly minorities and patients living in rural areas. It also worries me that many patients in Latin America will not have access to the drug, This, sadly, does not affect how impactful the study is. #LCSM |
| Eric Bernicker @EricBernicker That's what my radiation therapy colleagues tell me at tumor board :) It makes sense but the question remains of patient selection #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc @jillfeldman4 @NarjustDumaMD @JFreemanDaily T2. We are only just starting to sort out selectively combining local therapy with systemic therapy. Tons to learn in both initally diagnosed disease, initially metastatic disease, and recurrent disease. #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @subatomicdoc @NarjustDumaMD @JFreemanDaily i am just gonna go adea and quote @JackWestMD again ... #LCSM https://t.co/hP9fBPdf6A |
| Dave Bjork @bjork5 @JFreemanDaily @jillfeldman4 @ivybelkins @christine_lovly @LeciaSequist @Jbauml Awesome!! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @EricBernicker: That's what my radiation therapy colleagues tell me at tumor board :) It makes sense but the question remains of patient selection #LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: That's what my radiation therapy colleagues tell me at tumor board :) It makes sense but the question remains of patient selection #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @subatomicdoc: @jillfeldman4 @NarjustDumaMD @JFreemanDaily T2. We are only just starting to sort out selectively combining local therapy with systemic therapy. Tons to learn in both initally diagnosed disease, initially metastatic disease, and recurrent disease. #lcsm |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @jillfeldman4 @NarjustDumaMD @JFreemanDaily T2. We are only just starting to sort out selectively combining local therapy with systemic therapy. Tons to learn in both initally diagnosed disease, initially metastatic disease, and recurrent disease. #lcsm |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @jillfeldman4 @subatomicdoc @JFreemanDaily I would say that depends of each patient, which symptoms are the metastases causing and long term plan. Open communication is always key. #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @JackWestMD This was one of the successful therapies at #ASCO20, with data in multiple tumor types presented #HER2MT, with impressive RR in #NSCLC #LCSM |
 | Stephen V Liu, MD @StephenVLiu @HenningWillers Impressive OS difference. Maybe a bit surprised about the lack of difference in toxicity given the higher dose. I look forward to seeing the manuscript. Hoping a large phase 3 is in the works... #LCSM |
| Dave Bjork @bjork5 @BrendonStilesMD Hey Brendon! #LCSM 🤠 |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily Has no one mentioned #ADAURA yet? Everyone scared of @JackWestMD? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: @JackWestMD This was one of the successful therapies at #ASCO20, with data in multiple tumor types presented #HER2MT, with impressive RR in #NSCLC #LCSM |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @jillfeldman4 @subatomicdoc @JFreemanDaily I would say that depends of each patient, which symptoms are the metastases causing and long term plan. Open communication is always key. #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @JackWestMD This was one of the successful therapies at #ASCO20, with data in multiple tumor types presented #HER2MT, with impressive RR in #NSCLC #LCSM |
| H. Jack West, MD @JackWestMD @ArpanAshokPatel A colleague raised point these nivo/ipi combos give option of comparable efficacy as chemo/pembro but still leave option of platinum doublet upon progression. That got me thinking it's a reasonable longitudinal plan. And some say nivo/ipi has given longest responses. #LCSM |
| Dr. Amy C. Moore @acmoorephd When you are trying to cook and Tweet at the same time #lcsm https://t.co/wtnmuN20rX |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @HenningWillers: @subatomicdoc @NarjustDumaMD @JFreemanDaily i am just gonna go adea and quote @JackWestMD again ... #LCSM https://t.co/hP9fBPdf6A |
| Brendon Stiles @BrendonStilesMD @bjork5 Hi Dave! Hope you are well and safe! #lcsm |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @JFreemanDaily: @subatomicdoc @NarjustDumaMD @HenningWillers SINDAS – first-line TKI (with upfront rads vs no rads) in oligometastatic EGFR NSCLC –up to 5 mets (Abs 9508) https://t.co/riZ3DQNJTp #ASCO20 #LCSM https://t.co/BRlCTa6OCR |
| Henning Willers, MD (he/him/his) @HenningWillers A2 Love this one, as it is on clinical NGS panels already, as is KRAS/TP53 which also associates with radioresistance. BUT, are we going to have it impact clinical decision making ?? #LCSM |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @HenningWillers Impressive OS difference. Maybe a bit surprised about the lack of difference in toxicity given the higher dose. I look forward to seeing the manuscript. Hoping a large phase 3 is in the works... #LCSM |
| Janet Freeman-Daily @JFreemanDaily Happy to see more #SCLC options KEYNOTE-604 – first line pembro vs placebo+platinum-etoposide for extensive SCLC (Abs 9001) https://t.co/iMT87xrMxj CASPIAN – first-line durvalumab±tremelimumab+platinum-etoposide for extensive SCLC (Abs 9002) https://t.co/lsxu91f60t #LCSM #ASCO20 https://t.co/ljPArvRi82 |
| #LCSM Chat @lcsmchat RT @JackWestMD: @ArpanAshokPatel A colleague raised point these nivo/ipi combos give option of comparable efficacy as chemo/pembro but still leave option of platinum doublet upon progression. That got me thinking it's a reasonable longitudinal plan. And some say nivo/ipi has given longest responses. #LCSM |
| Eric Bernicker @EricBernicker T2 The study on smoking cessation and benefit prior to surgery was important and reminds docs never to be nihilistic when it comes to urging people to stop using tobacco #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Lol. It's you we fear, @BrendonStilesMD! #LCSM |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily @JackWestMD Ahhh.....seeing some below. #lcsm |
| Unmasking the Reality of Lung Cancer @UnmaskingC RT @JFreemanDaily: T2. What were the top abstracts at #ASCO20 specifically about lung cancer (screening, diagnosis, treatment, care)?#LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JackWestMD: @ArpanAshokPatel A colleague raised point these nivo/ipi combos give option of comparable efficacy as chemo/pembro but still leave option of platinum doublet upon progression. That got me thinking it's a reasonable longitudinal plan. And some say nivo/ipi has given longest responses. #LCSM |
 | SOMERA Sociedad Mexicana de Radioterapeutas @somera_mx RT @drcoronacruz: Turno de los #radonc, podcast "Lung Cancer Considered" sobre Radio-Oncología, cáncer de pulmón y #COVID19 @IASLC @somera_mx @loladelamata @MichRadioactiva #LCSM 👉🏽 https://t.co/lN3OfrMsVa |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @JackWestMD @ArpanAshokPatel But we have to remember that for some patients there may never be 2nd line therapy, so we have to choose our "best" approach first #LCSM |
| H. Jack West, MD @JackWestMD @HenningWillers @subatomicdoc @NarjustDumaMD @JFreemanDaily I don't think we can declare this the clear standard of care, as it's not a huge trial & control arm under-performed, but it's yet another convincingly positive trial for consol SBRT in a setting where all data converge on the same conclusion. I offer this to selected pts. #LCSM |
| Stephen V Liu, MD @StephenVLiu @JFreemanDaily @subatomicdoc @NarjustDumaMD @HenningWillers A big shortcoming was the lack of salvage TKI therapy. Only chemo was given at the time of progression. But the rationale is solid; a similar strategy to upfront chemotherapy. I’d like to see this replicated with osimertinib. #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers @NarjustDumaMD @subatomicdoc @JFreemanDaily c/w importance of cytoreduction to delay drug resistance, but doing SBRT as consolidation at time of max TKI response more compelling (also target volume will be smaller) #lcsm |
| Jill Feldman @jillfeldman4 @EricBernicker And side effects are a walk in the park compared to TKI & surgery with potential huge benefit. It's really individual, case by case because trials tough. How do you get big trials funded without actual 'drugs'? #LCSM |
| Brendon Stiles @BrendonStilesMD @TimAllenMDJD #ADAURA - emphasizing the need for good pathologists and molecular staging even more! #lcsm |
| #LCSM Chat @lcsmchat @acmoorephd Tell me about it. Grandbaby helps gramps working from home. #lcsm https://t.co/oRZv0LKSqQ |
| Eric Bernicker @EricBernicker We are not scared of Jack. We are scared of Nate Pennell 😂😂 #LCSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: A2 Love this one, as it is on clinical NGS panels already, as is KRAS/TP53 which also associates with radioresistance. BUT, are we going to have it impact clinical decision making ?? #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Happy to see more #SCLC options KEYNOTE-604 – first line pembro vs placebo+platinum-etoposide for extensive SCLC (Abs 9001) https://t.co/iMT87xrMxj CASPIAN – first-line durvalumab±tremelimumab+platinum-etoposide for extensive SCLC (Abs 9002) https://t.co/lsxu91f60t #LCSM #ASCO20 https://t.co/ljPArvRi82 |
| #LCSM Chat @lcsmchat RT @EricBernicker: T2 The study on smoking cessation and benefit prior to surgery was important and reminds docs never to be nihilistic when it comes to urging people to stop using tobacco #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @JackWestMD @ArpanAshokPatel But we have to remember that for some patients there may never be 2nd line therapy, so we have to choose our "best" approach first #LCSM |
| #LCSM Chat @lcsmchat RT @JackWestMD: @HenningWillers @subatomicdoc @NarjustDumaMD @JFreemanDaily I don't think we can declare this the clear standard of care, as it's not a huge trial & control arm under-performed, but it's yet another convincingly positive trial for consol SBRT in a setting where all data converge on the same conclusion. I offer this to selected pts. #LCSM |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD @JackWestMD ADAURA was the first #lungcancer abstract mentioned! See what happens when you're late? #LCSM |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @JFreemanDaily @subatomicdoc @NarjustDumaMD @HenningWillers A big shortcoming was the lack of salvage TKI therapy. Only chemo was given at the time of progression. But the rationale is solid; a similar strategy to upfront chemotherapy. I’d like to see this replicated with osimertinib. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD 2d that @EricBernicker #LCSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: @NarjustDumaMD @subatomicdoc @JFreemanDaily c/w importance of cytoreduction to delay drug resistance, but doing SBRT as consolidation at time of max TKI response more compelling (also target volume will be smaller) #lcsm |
 | Kuan-Wen Chen @ymouch RT @JFreemanDaily: @subatomicdoc @NarjustDumaMD @HenningWillers SINDAS – first-line TKI (with upfront rads vs no rads) in oligometastatic EGFR NSCLC –up to 5 mets (Abs 9508) https://t.co/riZ3DQNJTp #ASCO20 #LCSM https://t.co/BRlCTa6OCR |
| Brendon Stiles @BrendonStilesMD @EricBernicker They are a scary duo! #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: @EricBernicker And side effects are a walk in the park compared to TKI & surgery with potential huge benefit. It's really individual, case by case because trials tough. How do you get big trials funded without actual 'drugs'? #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers @EricBernicker well, it's not that #radiotherapy will not work, but intensification is needed, either higher dose or #RTdrugcombo #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @TimAllenMDJD #ADAURA - emphasizing the need for good pathologists and molecular staging even more! #lcsm |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @StephenVLiu @JFreemanDaily @subatomicdoc @HenningWillers I agree, Osimertinib is the new SOC and that will help. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: @JackWestMD @ArpanAshokPatel But we have to remember that for some patients there may never be 2nd line therapy, so we have to choose our "best" approach first #LCSM |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @MattSmeltzer @CharuAggarwalMD @JFreemanDaily Drug price reduction, international collaborations and programs tailored to Latin America will be necessary. #LCSM |
| Kuan-Wen Chen @ymouch #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers @jillfeldman4 @NarjustDumaMD @subatomicdoc @JFreemanDaily better to do at nadir of TKI response IMHO #LCSM |
| Lisa Briggs @livinglife82 Theres definitely a high level of concern amongst the #lungcancer community regarding #COVIDー19. It’s so disheartening to see so many people ignoring social distancing rules dispite those with #lungcancer being extra vigilant. Hard to feel ‘normal’ & safe at the same time. #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @HenningWillers: @EricBernicker well, it's not that #radiotherapy will not work, but intensification is needed, either higher dose or #RTdrugcombo #LCSM |
| Brendon Stiles @BrendonStilesMD #ASCO20 take home for me: science and great drugs continue to move into earlier stage lung cancer. We need to broadly test these patients now. #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD #TargetedTherapy calls for #NGS #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Can't argue with @BrendonStilesMD #PatientsFirst #LCSM |
| Dave Bjork @bjork5 This! 👇 #LCSM |
| Janet Freeman-Daily @JFreemanDaily We’ll shift to Topic T3 next … #LCSM |
| Brendon Stiles @BrendonStilesMD Also, time for surgeons to recognize that we don't always "get it all" and that there are adjuvant options out there. #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @EricBernicker well, it's not that #radiotherapy will not work, but intensification is needed, either higher dose or #RTdrugcombo #LCSM |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @StephenVLiu @JFreemanDaily @subatomicdoc @HenningWillers I agree, Osimertinib is the new SOC and that will help. #LCSM |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @MattSmeltzer @CharuAggarwalMD @JFreemanDaily Drug price reduction, international collaborations and programs tailored to Latin America will be necessary. #LCSM |
| #LCSM Chat @lcsmchat RT @ymouch: #LCSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: @jillfeldman4 @NarjustDumaMD @subatomicdoc @JFreemanDaily better to do at nadir of TKI response IMHO #LCSM |
| #LCSM Chat @lcsmchat RT @livinglife82: Theres definitely a high level of concern amongst the #lungcancer community regarding #COVIDー19. It’s so disheartening to see so many people ignoring social distancing rules dispite those with #lungcancer being extra vigilant. Hard to feel ‘normal’ & safe at the same time. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: Also, time for surgeons to recognize that we don't always "get it all" and that there are adjuvant options out there. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #ASCO20 take home for me: #ASCO20 take home for me: science and great drugs continue to move into earlier stage lung cancer. We need to broadly test these patients now. #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: #TargetedTherapy calls for #NGS #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @bjork5: This! 👇 #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Also, time for surgeons to recognize that we don't always "get it all" and that there are adjuvant options out there. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We’ll shift to Topic T3 next … #LCSM |
| Janet Freeman-Daily @JFreemanDaily T3. What key abstracts at #ASCO20 related to policy or patient care might influence lung cancer care? #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers @JFreemanDaily @BrendonStilesMD @JackWestMD A2 who thinks adjuvant osi in ADAURA simply delays tumor regrowth especially in stage IIIA #EGFR #lungcancer until after discontinuation of osi? #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: #ASCO20 take home for me: #ASCO20 take home for me: science and great drugs continue to move into earlier stage lung cancer. We need to broadly test these patients now. #lcsm |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @JackWestMD @ArpanAshokPatel Dropoff rates between 1L and 2L therapy are huge, and we cannot overlook those. #LCSM |
| Brendon Stiles @BrendonStilesMD T2. Interested to hear from patients. Is disease free survival an important endpoint? It seems to be to my patients, who hang on whether or not their scan shows new disease, despite being asymptomatic. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3. What key abstracts at #ASCO20 related to policy or patient care might influence lung cancer care? #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @livinglife82: Theres definitely a high level of concern amongst the #lungcancer community regarding #COVIDー19. It’s so disheartening to see so many people ignoring social distancing rules dispite those with #lungcancer being extra vigilant. Hard to feel ‘normal’ & safe at the same time. #LCSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: @JFreemanDaily @BrendonStilesMD @JackWestMD A2 who thinks adjuvant osi in ADAURA simply delays tumor regrowth especially in stage IIIA #EGFR #lungcancer until after discontinuation of osi? #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @JackWestMD @ArpanAshokPatel Dropoff rates between 1L and 2L therapy are huge, and we cannot overlook those. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Can't wait for the end of this #LCSM twitterchat to thank @JFreemanDaily for hosting! |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Interested to hear from patients. Is disease free survival an important endpoint? It seems to be to my patients, who hang on whether or not their scan shows new disease, despite being asymptomatic. #lcsm |
| Henning Willers, MD (he/him/his) @HenningWillers @ProjectBreath @NarjustDumaMD @MattSmeltzer @CharuAggarwalMD @JFreemanDaily and insurances do not pay for NGS testing in stage I-III #lungcancer, so much useful info we are missing out on there :-( #lcsm |
 | brunolarvol.eth – web3 @brunolarvol RT @CharuAggarwalMD: #ASCO20 Tiragolumab (Anti-TIGIT) + Atezolizumab vs Atezo + placebo in first line management of metastatic PD-L1+, increased RR and PFS seen in PDL-1 High patients, no significant AE signal. Interesting chemo-free approach for our WT patients with PD-L1>50% #LCSM Slides by Dr. Dy. https://t.co/NbfZJzlR4U |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: @JackWestMD @ArpanAshokPatel Dropoff rates between 1L and 2L therapy are huge, and we cannot overlook those. #LCSM |
| Jill Feldman @jillfeldman4 THIS! What good are new therapies if the patients who need them aren't being tested? NGS is a MUST. But I believe it's up to us to educate, esp those at comm hospitals. We can barely keep up w/lc research so we can't expect them to. They need mentors (no pressure 😳)#LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @TimAllenMDJD @JFreemanDaily She is doing an amazing job as always! #LCSM |
| Brendon Stiles @BrendonStilesMD @CharuAggarwalMD @JackWestMD @ArpanAshokPatel I feel like this point was not driven home. it is incredibly important. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T3. What key abstracts at #ASCO20 related to policy or patient care might influence lung cancer care? #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers RT @BrendonStilesMD: Also, time for surgeons to recognize that we don't always "get it all" and that there are adjuvant options out there. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @TimAllenMDJD Thanks! There's a lot of content to choose from. #LCSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: @ProjectBreath @NarjustDumaMD @MattSmeltzer @CharuAggarwalMD @JFreemanDaily and insurances do not pay for NGS testing in stage I-III #lungcancer, so much useful info we are missing out on there :-( #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: THIS! What good are new therapies if the patients who need them aren't being tested? NGS is a MUST. But I believe it's up to us to educate, esp those at comm hospitals. We can barely keep up w/lc research so we can't expect them to. They need mentors (no pressure 😳)#LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @HenningWillers @ProjectBreath @NarjustDumaMD @MattSmeltzer @JFreemanDaily Reimbursement will have to follow #approvals #LCSM |
| Eric Bernicker @EricBernicker Absolutely gonna put the first part of that sentence on bumper stickers and put it on my surgical colleagues cars #LCSM |
| Stephen V Liu, MD @StephenVLiu #T3 I think this work by @n8pennell discussing cost of NGS and single gene tests should influence policy going forward - particularly in light of the many novel targets we now need to identify! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Needs good research info to change the paradigm. #LCSM |
| Dave Bjork @bjork5 @TimAllenMDJD @JFreemanDaily She’s so good at this 🙌 #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers RT @EricBernicker: Absolutely gonna put the first part of that sentence on bumper stickers and put it on my surgical colleagues cars #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jillfeldman4: THIS! What good are new therapies if the patients who need them aren't being tested? NGS is a MUST. But I believe it's up to us to educate, esp those at comm hospitals. We can barely keep up w/lc research so we can't expect them to. They need mentors (no pressure 😳)#LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: Absolutely gonna put the first part of that sentence on bumper stickers and put it on my surgical colleagues cars #LCSM |
| Matthew Katz, MD 🇺🇸 💜 @subatomicdoc RT @HenningWillers: @ProjectBreath @NarjustDumaMD @MattSmeltzer @CharuAggarwalMD @JFreemanDaily and insurances do not pay for NGS testing in stage I-III #lungcancer, so much useful info we are missing out on there :-( #lcsm |
| #LCSM Chat @lcsmchat RT @StephenVLiu: #T3 I think this work by @n8pennell discussing cost of NGS and single gene tests should influence policy going forward - particularly in light of the many novel targets we now need to identify! #LCSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Needs good research info to change the paradigm. #LCSM |
| Janet Freeman-Daily @JFreemanDaily Found this one interesting. Changes in cancer mortality rates after the adoption of the Affordable Care Act (Abs 2003). Cancer mortality in Medicare expansion states definitely went down after ACA implemented. https://t.co/sXdkcLFr0a #LCSM #ASCO20 https://t.co/bhbxD5nzeJ |
| Brendon Stiles @BrendonStilesMD @HenningWillers @JFreemanDaily @JackWestMD I think it will kill some tumors and cure some patients. #lcsm |
| Kristin Ito @KAdvocate_LCAM @jillfeldman4 My hope is with many of these BIG meetings going virtual, more comm hospital care team members can access the needed research! And patients/caregivers have easier access to know what questions to ask their care teams #LCSM |
| Brendon Stiles @BrendonStilesMD @HenningWillers @JFreemanDaily @JackWestMD Or at least kill/cure some micrometastatic disease. #lcsm |
| Eric Bernicker @EricBernicker I think after Adaura they will need to at least pay for EGFR..so we might as well get the whole schmear #LCSM |
| Dr. Amy C. Moore @acmoorephd Nice way to summarize it! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Found this one interesting. Changes in cancer mortality rates after the adoption of the Affordable Care Act (Abs 2003). Cancer mortality in Medicare expansion states definitely went down after ACA implemented. https://t.co/sXdkcLFr0a #LCSM #ASCO20 https://t.co/bhbxD5nzeJ |
 | CancerWarrior51 @myVPisAGIRL RT @TestLungCancer: After his mom’s diagnosis, PGA golf champion Jason Day was given a lot of advice about how to help her through Stage IV non-small cell #lungcancer diagnosis. Here is what he learned about finding the right treatment options. #LCSM |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: @jillfeldman4 My hope is with many of these BIG meetings going virtual, more comm hospital care team members can access the needed research! And patients/caregivers have easier access to know what questions to ask their care teams #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @StephenVLiu: #T3 I think this work by @n8pennell discussing cost of NGS and single gene tests should influence policy going forward - particularly in light of the many novel targets we now need to identify! #LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: I think after Adaura they will need to at least pay for EGFR..so we might as well get the whole schmear #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD I hope and wish that the results of #ADAURA don't mean doing "less optimal" surgery #LCSM. Surgery and chemotherapy are still the only modalities that have proven OS data |
| H. Jack West, MD @JackWestMD @HenningWillers @JFreemanDaily @BrendonStilesMD A2: I think that's most of the benefit, just suppressing. However, some minority of pts will progress quickly (mainly in brain) & miss the chance; it's also possible that osi will have much greater efficacy for micro vs. macrometastatic dzs. Just need to see OS data. #LCSM |
| Dr. Amy C. Moore @acmoorephd RT @StephenVLiu: #T3 I think this work by @n8pennell discussing cost of NGS and single gene tests should influence policy going forward - particularly in light of the many novel targets we now need to identify! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @EricBernicker: I think after Adaura they will need to at least pay for EGFR..so we might as well get the whole schmear #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD Amen! #VirtualMeetings #LCSM |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @ProjectBreath @MattSmeltzer @CharuAggarwalMD @JFreemanDaily Getting EGFR testing in my country is pretty much a close impossible task for the working class, many women are never smoker with lung cancer there, I hope we can as a community help diminish the gap. #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: I hope and wish that the results of #ADAURA don't mean doing "less optimal" surgery #LCSM. Surgery and chemotherapy are still the only modalities that have proven OS data |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: I hope and wish that the results of #ADAURA don't mean doing "less optimal" surgery #LCSM. Surgery and chemotherapy are still the only modalities that have proven OS data |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD DFS is important, but some early stage NSCLC patients won't want to stay on TKI forever, especially if they think surgery "cured" them. I'm happy to be NED, but side effects do impact #QoL. Tx choice requires #SDM. #LCSM #ASCO20 |
| brunolarvol.eth – web3 @brunolarvol RT @LeciaSequist: For those who worried that DFS may be altered in ADAURA because of frequent monitoring, this monitoring schedule seems on par with SOC #LCSM #ASCO20 @EGFRResisters https://t.co/csxxCI8nDu |
| Henning Willers, MD (he/him/his) @HenningWillers @BrendonStilesMD @JFreemanDaily @JackWestMD in the lab TKI treatment kills like ~95% of cell present, but not 100% ... #lcsm |
| Eric Bernicker @EricBernicker Of course full staging with PET and MRI brain prior to surgery would have helped analyze the data #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers RT @JackWestMD: @HenningWillers @JFreemanDaily @BrendonStilesMD A2: @HenningWillers @JFreemanDaily @BrendonStilesMD A2: I think that's most of the benefit, just suppressing. However, some minority of pts will progress quickly (mainly in brain) & miss the chance; it's also possible that osi will have much greater efficacy for micro vs. macrometastatic dzs. Just need to see OS data. #LCSM |
| #LCSM Chat @lcsmchat RT @JackWestMD: @HenningWillers @JFreemanDaily @BrendonStilesMD A2: @HenningWillers @JFreemanDaily @BrendonStilesMD A2: I think that's most of the benefit, just suppressing. However, some minority of pts will progress quickly (mainly in brain) & miss the chance; it's also possible that osi will have much greater efficacy for micro vs. macrometastatic dzs. Just need to see OS data. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD This #LCSM |
| #LCSM Chat @lcsmchat RT @NarjustDumaMD: @ProjectBreath @MattSmeltzer @CharuAggarwalMD @JFreemanDaily Getting EGFR testing in my country is pretty much a close impossible task for the working class, many women are never smoker with lung cancer there, I hope we can as a community help diminish the gap. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD DFS is important, but some early stage NSCLC patients won't want to stay on TKI forever, especially if they think surgery "cured" them. I'm happy to be NED, but side effects do impact #QoL. Tx choice requires #SDM. #LCSM #ASCO20 |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD @JFreemanDaily @JackWestMD in the lab TKI treatment kills like ~95% of cell present, but not 100% ... #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @BrendonStilesMD DFS is important, but some early stage NSCLC patients won't want to stay on TKI forever, especially if they think surgery "cured" them. I'm happy to be NED, but side effects do impact #QoL. Tx choice requires #SDM. #LCSM #ASCO20 |
| #LCSM Chat @lcsmchat RT @EricBernicker: Of course full staging with PET and MRI brain prior to surgery would have helped analyze the data #LCSM |
| Henning Willers, MD (he/him/his) @HenningWillers @TimAllenMDJD yes, it is a tall order #lcsm |
| Sabin Motwani @sabinbmotwanimd A3. While not presented at #ASCO20, long-term results of @drdavidpalma SABR-COMET were published this week, looking at the role of SABR in oligometastatic cancers showing a 25% OS inc w SABR. Caveats.but this is a practice changing study. #radonc #lcsm https://t.co/WUPNnHD6hM |
| Henning Willers, MD (he/him/his) @HenningWillers @EricBernicker there is some elegance to that :-) #lcsm |
| Brendon Stiles @BrendonStilesMD T3. There was some great work from @ACCCBuzz regarding current challenges to testing and care. https://t.co/HLlbz8ntn9 #lcsm |
| Lung Cancer Sux @LungCancerSux RT @sabinbmotwanimd: A3. While not presented at #ASCO20, long-term results of @drdavidpalma SABR-COMET were published this week, looking at the role of SABR in oligometastatic cancers showing a 25% OS inc w SABR. Caveats.but this is a practice changing study. #radonc #lcsm https://t.co/WUPNnHD6hM |
| #LCSM Chat @lcsmchat RT @sabinbmotwanimd: A3. While not presented at #ASCO20, long-term results of @drdavidpalma SABR-COMET were published this week, looking at the role of SABR in oligometastatic cancers showing a 25% OS inc w SABR. Caveats.but this is a practice changing study. #radonc #lcsm https://t.co/WUPNnHD6hM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. There was some great work from @ACCCBuzz regarding current challenges to testing and care. https://t.co/HLlbz8ntn9 #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. There was some great work from @ACCCBuzz regarding current challenges to testing and care. https://t.co/HLlbz8ntn9 #lcsm |
| Henning Willers, MD (he/him/his) @HenningWillers RT @sabinbmotwanimd: A3. While not presented at #ASCO20, long-term results of @drdavidpalma SABR-COMET were published this week, looking at the role of SABR in oligometastatic cancers showing a 25% OS inc w SABR. Caveats.but this is a practice changing study. #radonc #lcsm https://t.co/WUPNnHD6hM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @sabinbmotwanimd @drdavidpalma Very small number of patients with #NSCLC, and IMO, should not be practice changing (just yet) #LCSM |
| Lung Cancer Sux @LungCancerSux RT @BrendonStilesMD: T3. There was some great work from @ACCCBuzz regarding current challenges to testing and care. https://t.co/HLlbz8ntn9 #lcsm |
| Janet Freeman-Daily @JFreemanDaily @HenningWillers @BrendonStilesMD @JackWestMD Who thinks adjuvant TKI simply delays recurrence? ME! Until we have evidence of extended OS after stopping TKI, I ain't gonna stop taking my TKI post-chemo/rad despite 7.5 yrs NED. #LCSM |
| H. Jack West, MD @JackWestMD RT @BrendonStilesMD: T3. There was some great work from @ACCCBuzz regarding current challenges to testing and care. https://t.co/HLlbz8ntn9 #lcsm |
| Brendon Stiles @BrendonStilesMD @CharuAggarwalMD I am going to still do optimal surgery for you @CharuAggarwalMD! And for patients. #lcsm |
| Jill Feldman @jillfeldman4 @BrendonStilesMD You get what you see. The stealth of lung cancer is nasty and ruthless! My brother equates the cells to cockroaches - you may only see one or two, but there are millions more 🤮 Unfortunately that's the case sometimes...#LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @sabinbmotwanimd @drdavidpalma Very small number of patients with #NSCLC, and IMO, should not be practice changing (just yet) #LCSM |
| Eric Bernicker @EricBernicker Yes! This should have had much more attention, especially by law makers. Real world evidence of medical benefit from policy being enacted #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @HenningWillers @BrendonStilesMD @JackWestMD Who thinks adjuvant TKI simply delays recurrence? ME! Until we have evidence of extended OS after stopping TKI, I ain't gonna stop taking my TKI post-chemo/rad despite 7.5 yrs NED. #LCSM |
| Brendon Stiles @BrendonStilesMD @HenningWillers @JFreemanDaily @JackWestMD Better than #SBRT.... #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: @BrendonStilesMD You get what you see. The stealth of lung cancer is nasty and ruthless! My brother equates the cells to cockroaches - you may only see one or two, but there are millions more 🤮 Unfortunately that's the case sometimes...#LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: Yes! This should have had much more attention, especially by law makers. Real world evidence of medical benefit from policy being enacted #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @EricBernicker: Yes! This should have had much more attention, especially by law makers. Real world evidence of medical benefit from policy being enacted #LCSM |
| Brendon Stiles @BrendonStilesMD @HenningWillers @JFreemanDaily @JackWestMD Couldn't help it... #lcsm |
 | c.c.lipscomb @TNradonc RT @DrLesterColl: Multicenter (n=710) obs study of 1st line SRS v WBRT for SCLC brain mets in @JAMAOnc #lcsm 👉 SRS med OS 8.5 mos, 11 mos for 1 lesion; 33.5% rx salvage SRS, 16.1% rx salvage WBRT 👉⬆️Time to CNS prog w/ WBRT but similar OS 👉Encouraging outcomes for SRS! https://t.co/erivtXEUha https://t.co/cjmOeSlPb3 |
| Matthew Smeltzer @MattSmeltzer Very sad. It sounds like EGFR testing alone may be a starting place, before tackling NGS |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD @HenningWillers @JackWestMD Some stg 4 NSCLC patients on TKIs (in online biomarker groups) have experimented with taking TKI breaks (2-3 months) after long periods of NED. So far, they've all recurred. Some had previous chemo/rad. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD @n8pennell FTW #LCSM |
| Kristin Ito @KAdvocate_LCAM For additional #ASCO summary info, a special episode of "Lung Cancer Considered," features, @CBelaniMD, speaking with @StephenVLiu about the #lungcancer research presented at the @ASCO #LCSM Listen here -> https://t.co/JwrSRvalgn |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @KAdvocate_LCAM: For additional #ASCO summary info, a special episode of "Lung Cancer Considered," features, @CBelaniMD, speaking with @StephenVLiu about the #lungcancer research presented at the @ASCO #LCSM Listen here -> https://t.co/JwrSRvalgn |
| Brendon Stiles @BrendonStilesMD T3. Also liked this one from @ACCCBuzz https://t.co/phr8sEb9JA #lcsm |
 | Kathleen Skambis @KathleenSkambis RT @EricBernicker: Yes! This should have had much more attention, especially by law makers. Real world evidence of medical benefit from policy being enacted #LCSM |
| H. Jack West, MD @JackWestMD @BrendonStilesMD @JFreemanDaily C'mon...I'm impressed that it's a pos trial. It's just Q of how great it is to see DFS benefit during time pts are still on EGFR TKI -- will pts do just as well for survival w/osi on relapse & not over-treat many? And should we care about society cost of $200-250K/yr/pt? #LCSM |
 | Matthew Steliga MD FACS @SteligaMD RT @EricBernicker: Yes! This should have had much more attention, especially by law makers. Real world evidence of medical benefit from policy being enacted #LCSM |
| Janet Freeman-Daily @JFreemanDaily T4. What upsides or downsides do you see for the #ASCO20 virtual meeting format (compared to the usual in-person format)? (I'm expecting a few strong opinions here) #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD @HenningWillers @JackWestMD Some stg 4 NSCLC patients on TKIs (in online biomarker groups) have experimented with taking TKI breaks (2-3 months) after long periods of NED. So far, they've all recurred. Some had previous chemo/rad. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. Also liked this one from @ACCCBuzz https://t.co/phr8sEb9JA #lcsm |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: For additional #ASCO summary info, a special episode of "Lung Cancer Considered," features, @CBelaniMD, speaking with @StephenVLiu about the #lungcancer research presented at the @ASCO #LCSM Listen here -> https://t.co/JwrSRvalgn |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Also liked this one from @ACCCBuzz https://t.co/phr8sEb9JA #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: @BrendonStilesMD @JFreemanDaily C'mon...I'm impressed that it's a pos trial. It's just Q of how great it is to see DFS benefit during time pts are still on EGFR TKI -- will pts do just as well for survival w/osi on relapse & not over-treat many? And should we care about society cost of $200-250K/yr/pt? #LCSM |
| Stephen V Liu, MD @StephenVLiu RT @KAdvocate_LCAM: For additional #ASCO summary info, a special episode of "Lung Cancer Considered," features, @CBelaniMD, speaking with @StephenVLiu about the #lungcancer research presented at the @ASCO #LCSM Listen here -> https://t.co/JwrSRvalgn |
| Jill Feldman @jillfeldman4 @JFreemanDaily @HenningWillers @BrendonStilesMD @JackWestMD Do you really want to know what I think? Not a simple yes or no. Stay tuned..... #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4. What upsides or downsides do you see for the #ASCO20 virtual meeting format (compared to the usual in-person format)? (I'm expecting a few strong opinions here) #LCSM |
| Lisa Briggs @livinglife82 RT @JFreemanDaily: @BrendonStilesMD @HenningWillers @JackWestMD Some stg 4 NSCLC patients on TKIs (in online biomarker groups) have experimented with taking TKI breaks (2-3 months) after long periods of NED. So far, they've all recurred. Some had previous chemo/rad. #LCSM |
| Sabin Motwani @sabinbmotwanimd @CharuAggarwalMD @drdavidpalma Yes you are correct. Still important to enroll on Phase III @NRGonc studies like @IyengarPuneeth NRG LU-002 to replicate OS benefits and to develop biomarkers predictive of benefit with SABR, but still an impressive study using SABR. #lcsm #radonc |
| Brendon Stiles @BrendonStilesMD @jillfeldman4 @JFreemanDaily @HenningWillers @JackWestMD Umm....yeah. #lcsm |
| Eric Bernicker @EricBernicker Upside; massive decrease in the meeting's carbon footprint at a time of ongoing concerns of raging climate change. The downsides are insignificant compared to that #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Cost is always problematic. Need to transparently discuss, not ignore or leave it to others, #LCSM |
| Matthew Smeltzer @MattSmeltzer RT @BrendonStilesMD: T3. Also liked this one from @ACCCBuzz https://t.co/phr8sEb9JA #lcsm |
| Henning Willers, MD (he/him/his) @HenningWillers RT @sabinbmotwanimd: @CharuAggarwalMD @drdavidpalma Yes you are correct. Still important to enroll on Phase III @NRGonc studies like @IyengarPuneeth NRG LU-002 to replicate OS benefits and to develop biomarkers predictive of benefit with SABR, but still an impressive study using SABR. #lcsm #radonc |
| #LCSM Chat @lcsmchat RT @sabinbmotwanimd: @CharuAggarwalMD @drdavidpalma Yes you are correct. Still important to enroll on Phase III @NRGonc studies like @IyengarPuneeth NRG LU-002 to replicate OS benefits and to develop biomarkers predictive of benefit with SABR, but still an impressive study using SABR. #lcsm #radonc |
| Henning Willers, MD (he/him/his) @HenningWillers RT @JFreemanDaily: @HenningWillers @BrendonStilesMD @JackWestMD Who thinks adjuvant TKI simply delays recurrence? ME! Until we have evidence of extended OS after stopping TKI, I ain't gonna stop taking my TKI post-chemo/rad despite 7.5 yrs NED. #LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: Upside; massive decrease in the meeting's carbon footprint at a time of ongoing concerns of raging climate change. The downsides are insignificant compared to that #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD Agree, incredible effort by @drdavidpalma et al, and authors should be appalled #LCSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Cost is always problematic. Need to transparently discuss, not ignore or leave it to others, #LCSM |
| Vamsi Velcheti, MD @VamsiVelcheti I think bigger practical issue for me after #ASCO20 #ADURA is pts with EGFR stage III after definitive chemoRT- was never a big fan of Durva for these patient for several reasons- now tempted to give Osi for this very high risk population -ofcourse no data yet #LCSM |
| Stephen V Liu, MD @StephenVLiu RT @JFreemanDaily: Interesting to see results of a new ICI checkpoint CITYSCAPE – first line anti-TIGIT antibody tiragolumab+atezo vs placebo+atezo in PD-L1-selected stg 3/4 NSCLC (Abs 9503) https://t.co/D7C89yrnei #LCSM #ASCO20 https://t.co/bbXJbrz0di |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Agree, incredible effort by @drdavidpalma et al, and authors should be appalled #LCSM |
| Janet Freeman-Daily @JFreemanDaily T4: Upsides of virtual #ASCO: --get up just before sessions start on West Coast --can wear any shoes (or no shoes and feet are fine --patients attend FREE (along with ASCO members) --Posters are ALWAYS clear! #LCSM |
| #LCSM Chat @lcsmchat RT @VamsiVelcheti: I think bigger practical issue for me after #ASCO20 #ADURA is pts with EGFR stage III after definitive chemoRT- was never a big fan of Durva for these patient for several reasons- now tempted to give Osi for this very high risk population -ofcourse no data yet #LCSM |
| H. Jack West, MD @JackWestMD @JFreemanDaily @BrendonStilesMD @HenningWillers But there's big diff between st 4 & stage IB. Plenty of pts would be taking yrs (or vy poss indefinite) osi when they're already cured, but they can't know if it's because of osi or they're taking it as the equivalent of "shark repellent" -- doing nothing -- but no sharks. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: Upsides of virtual #ASCO: --get up just before sessions start on West Coast --can wear any shoes (or no shoes and feet are fine --patients attend FREE (along with ASCO members) --Posters are ALWAYS clear! #LCSM |
| Jill Feldman @jillfeldman4 I actually know (personally) 3 stage IV patients who had aggressive surgery and/or radiation to main tumor & mets and are off TKI. One has been for 5 yrs at least! Still NED. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T4: T4: Upsides of virtual #ASCO: --get up just before sessions start on West Coast --can wear any shoes (or no shoes and feet are fine --patients attend FREE (along with ASCO members) --Posters are ALWAYS clear! #LCSM |
| #LCSM Chat @lcsmchat RT @JackWestMD: @JFreemanDaily @BrendonStilesMD @HenningWillers But there's big diff between st 4 & stage IB. Plenty of pts would be taking yrs (or vy poss indefinite) osi when they're already cured, but they can't know if it's because of osi or they're taking it as the equivalent of "shark repellent" -- doing nothing -- but no sharks. #LCSM |
| Lung Cancer Sux @LungCancerSux @JFreemanDaily T4 - virtual sessions lacked lively Q&A. Easier to read when over #LCSM |
| Lisa Briggs @livinglife82 @jillfeldman4 @JFreemanDaily @HenningWillers @BrendonStilesMD @JackWestMD The suspense is killing me already @jillfeldman4 🤣🙈 #LCSM |
| Brendon Stiles @BrendonStilesMD T3. And this great effort from @MattSmeltzer and @ACCCBuzz on care in Medicaid patients. #lcsm https://t.co/AUQHLELxB8 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JackWestMD: @JFreemanDaily @BrendonStilesMD @HenningWillers But there's big diff between st 4 & stage IB. Plenty of pts would be taking yrs (or vy poss indefinite) osi when they're already cured, but they can't know if it's because of osi or they're taking it as the equivalent of "shark repellent" -- doing nothing -- but no sharks. #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: I actually know (personally) 3 stage IV patients who had aggressive surgery and/or radiation to main tumor & mets and are off TKI. One has been for 5 yrs at least! Still NED. #LCSM |
| #LCSM Chat @lcsmchat RT @LungCancerSux: @JFreemanDaily T4 - virtual sessions lacked lively Q&A. Easier to read when over #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. And this great effort from @MattSmeltzer and @ACCCBuzz on care in Medicaid patients. #lcsm https://t.co/AUQHLELxB8 |
| Janet Freeman-Daily @JFreemanDaily T4: More #ASCO Upsides --all seats have a clear view of slides --audio for most speakers was clear --coffee was cheap and instantly available #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: #ASCO20 take home for me: #ASCO20 take home for me: science and great drugs continue to move into earlier stage lung cancer. We need to broadly test these patients now. #lcsm |
| H. Jack West, MD @JackWestMD @VamsiVelcheti Understood, but one has proven OS benefit and is standard of care, & other is speculative & even after LAURA may only show DFS benefit. Just want to see well done trial that looks at OS as primary endpoint. #LCSM |
 | Oncopedia @onco_pedia RT @StephenVLiu: #T3 I think this work by @n8pennell discussing cost of NGS and single gene tests should influence policy going forward - particularly in light of the many novel targets we now need to identify! #LCSM |
| Janet Freeman-Daily @JFreemanDaily We’re in our final minutes - closing thoughts? #LCSM |
| Joni Fowler, PharmD, BCPP @jfowlerpharmd @JFreemanDaily #lcsm https://t.co/2Vpnhb0J0r |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: We’re in our final minutes - closing thoughts? #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: More #ASCO Upsides --all seats have a clear view of slides --audio for most speakers was clear --coffee was cheap and instantly available #LCSM |
| #LCSM Chat @lcsmchat RT @JackWestMD: @VamsiVelcheti Understood, but one has proven OS benefit and is standard of care, & other is speculative & even after LAURA may only show DFS benefit. Just want to see well done trial that looks at OS as primary endpoint. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We’re in our final minutes - closing thoughts? #LCSM |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @JFreemanDaily Love your outlook on this #EternalOptimist #LCSM |
| #LCSM Chat @lcsmchat RT @jfowlerpharmd: @JFreemanDaily #lcsm https://t.co/2Vpnhb0J0r |
| Eric Bernicker @EricBernicker Maybe if people liked me I would feel differently 😅 Come to think of it, my wife wasn't too happy I wasn't in Chicago for 5 days... #LCSM |
| Brendon Stiles @BrendonStilesMD T4. Damn....I just miss seeing people. Friends, patients, colleagues. The spontaneity of an encounter. Shared off the cuff ideas and comments. Wasn't the same. #lcsm |
 | Liza Henry McDonald @DocLHenry RT @HemeOncGators: #HOJournalClub tonight!! Let’s do this! #lcsm |
| #LCSM Chat @lcsmchat RT @EricBernicker: Maybe if people liked me I would feel differently 😅 Come to think of it, my wife wasn't too happy I wasn't in Chicago for 5 days... #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Damn....I just miss seeing people. Friends, patients, colleagues. The spontaneity of an encounter. Shared off the cuff ideas and comments. Wasn't the same. #lcsm |
| Jill Feldman @jillfeldman4 T4 I thought it was great considering, but I didn't really think there was an upside. Yes we could see & watch every abstract/poster/presentation. But, I learn best when I can annoy the doc beside me & I really missed seeing all my advocate/scientist/doc friends! #LCSM |
| Janet Freeman-Daily @JFreemanDaily T4: Downsides of virtual #ASCO20: --I MISS SEEING EVERYBODY! --Didn't get my daily 5-mile walk --Tough to see presentations when you can't get into the meeting #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #coronavirus #LCSM |
 | `((,(Dieter 'Hovekamp)))🇺🇦👥🤝👥🇷🇺 ☮️🕊️ @dhovekamp42 RT @jfowlerpharmd: @JFreemanDaily #lcsm https://t.co/2Vpnhb0J0r |
| Brendon Stiles @BrendonStilesMD @JackWestMD @JFreemanDaily @HenningWillers #lcsm https://t.co/WqAdv8I9U9 |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 I thought it was great considering, but I didn't really think there was an upside. Yes we could see & watch every abstract/poster/presentation. But, I learn best when I can annoy the doc beside me & I really missed seeing all my advocate/scientist/doc friends! #LCSM |
| Dr. Jan Marie Eberth @jmeberth @JFreemanDaily Like the idea of getting to rewatch content... also making meeting attendance more accessible for students, parents, patients, etc (travel is $$!) #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: Downsides of virtual #ASCO20: --I MISS SEEING EVERYBODY! --Didn't get my daily 5-mile walk --Tough to see presentations when you can't get into the meeting #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T4: T4: Downsides of virtual #ASCO20: --I MISS SEEING EVERYBODY! --Didn't get my daily 5-mile walk --Tough to see presentations when you can't get into the meeting #LCSM |
| #LCSM Chat @lcsmchat RT @jmeberth: @JFreemanDaily Like the idea of getting to rewatch content... also making meeting attendance more accessible for students, parents, patients, etc (travel is $$!) #LCSM |
| Dave Bjork @bjork5 @JFreemanDaily Thank you Janet for another great chat 😎 #LCSM |
| Brendon Stiles @BrendonStilesMD @JackWestMD @JFreemanDaily @HenningWillers I did not even know there was shark repellent. Does it cost as much as adjuvant therapy? #lcsm |
| Eric Bernicker @EricBernicker We are fortunate that we are in a tremendously hopeful and exciting time in the management of lung cancer and the future is bright #LCSM |
| Dr. Amy C. Moore @acmoorephd Upside: I got to do more science and fewer industry meetings than at most ASCOs #lcsm |
| #LCSM Chat @lcsmchat RT @EricBernicker: We are fortunate that we are in a tremendously hopeful and exciting time in the management of lung cancer and the future is bright #LCSM |
| H. Jack West, MD @JackWestMD Folks, great discussion. I need to sign off & sharpen my claws briefly before #HOJOURNALCLUB now about to start & focusing on adjuvant EGFR TKIs, as per SELECT trial & #ADAURA. #LCSM |
| #LCSM Chat @lcsmchat RT @acmoorephd: Upside: Upside: I got to do more science and fewer industry meetings than at most ASCOs #lcsm |
| Matthew Smeltzer @MattSmeltzer Thanks! Improving quality of care can be a long process, but very worth it! |
| Matthew Smeltzer @MattSmeltzer Thanks! Improving quality of care can be a long process, but very worth it! |
| Henning Willers, MD (he/him/his) @HenningWillers #LCSM Closing thoughts. Hoping for more #radonc participation next @ASCO Meeting 😁 https://t.co/EtcWK9m8L2 |
| #LCSM Chat @lcsmchat RT @JackWestMD: Folks, great discussion. I need to sign off & sharpen my claws briefly before #HOJOURNALCLUB now about to start & focusing on adjuvant EGFR TKIs, as per SELECT trial & #ADAURA. #LCSM |
 | HOJournalClub @HOJournalClub Welcome to the post #ASCO20 Journal club discussing a much anticipated topic from the plenary sessions📛 Please introduce yourselves here 👇🏾 (lurkers too 😅) ‼️Use the #HOjournalclub and #lcsm tonight ! https://t.co/dhlfa3c4lT |
| #LCSM Chat @lcsmchat RT @HenningWillers: #LCSM Closing thoughts. Hoping for more #radonc participation next @ASCO Meeting 😁 https://t.co/EtcWK9m8L2 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Especially during this difficult time I appreciate this extraordinary# #LCSM team. |
| Sabin Motwani @sabinbmotwanimd @CharuAggarwalMD @drdavidpalma I agree they should be applauded :) #LCSM |
| Janet Freeman-Daily @JFreemanDaily Thanks for joining #LCSM Chat for our review of #ASCO20 presentations for #lungcancer! Hope to see you at our next chat! |
| #LCSM Chat @lcsmchat RT @HOJournalClub: Welcome to the post #ASCO20 Journal club discussing a much anticipated topic from the plenary sessions📛 Please introduce yourselves here 👇🏾 (lurkers too 😅) ‼️Use the #HOjournalclub and #lcsm tonight ! https://t.co/dhlfa3c4lT |
| Dr. Amy C. Moore @acmoorephd Dinner is served. Think I’ll go think about #ASCO20 some more #lcsm https://t.co/6OypYlzfcs |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Thanks for joining #LCSM Chat for our review of #ASCO20 presentations for #lungcancer! Hope to see you at our next chat! |
| Lisa Briggs @livinglife82 Smart move...me either! Based on the outcomes witnessed by those who have attempted this, it hasn’t been positive yet...but there’s always #HOPE |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Thanks for joining #LCSM Chat for our review of #ASCO20 presentations for #lungcancer! Hope to see you at our next chat! |
| Liza Henry McDonald @DocLHenry Starting now!! @LoyolaOnc @LoyolaRadOncRes |
| Charu Aggarwal, MD, MPH @CharuAggarwalMD @JFreemanDaily Great discussion everyone! See you all soon! #LCSM |
| Narjust Florez (Duma), M.D. @NarjustFlorezMD @JFreemanDaily @lcsmchat Thank you @JFreemanDaily and @JackWestMD. Hope to see you soon. #lcsm |
| Kristin Ito @KAdvocate_LCAM Thank you @JFreemanDaily you are a true light with hosting! Treat yourself to some extra chocolate, solid LCSM Chat, my friend. #LCSM |
| Brendon Stiles @BrendonStilesMD T4. Nice aspects about Virtual. Will use this as definite rationale to go to less meetings - we all probably attend too many. But miss meeting people spontaneously who I may not meet at a virtual meeting. Wait a minute...didn't I meet many of you through twitter? #lcsm |
| Lillian Leigh @ProjectBreath @JFreemanDaily Thanks for moderating @JFreemanDaily. Lovely chatting with everyone! #LCSM |
 | gilberto lopes @GlopesMd Thank you #SingaporeSocietyofOncology @LucenceDx Tan Min Han, Rajesh Shah and Toh Chee Keong for a great discussion on #COVID19nCancer #LCSM #CCC19 @COVID19nCCC https://t.co/fSMB7Uqsus |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #Chocolate #LCSM |
 | Inas Abuali, MD @inas_md @HOJournalClub @DrMMurphy @DocLHenry @DevikaDasMD @JackWestMD I am excited about this! I am Inas, a heme/onc fellow at UC. #HOjournalclub #lcsm |
| Liza Henry McDonald @DocLHenry @HOJournalClub @DrMMurphy @DevikaDasMD @JackWestMD Liza, fellowship PD @LoyolaOnc. #GU oncology is my game, but I'm excited for tonight's discussion! #HOJournalClub #LCSM |
| Lillian Leigh @ProjectBreath RT @KAdvocate_LCAM: For additional #ASCO summary info, a special episode of "Lung Cancer Considered," features, @CBelaniMD, speaking with @StephenVLiu about the #lungcancer research presented at the @ASCO #LCSM Listen here -> https://t.co/JwrSRvalgn |
 | Mudit Chowdhary, MD @DrChowdharyMD @HenningWillers @ASCO Sorry to have missed @lcsmchat this month! Look forward to joining y’all again next time #lcsm |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily Thanks @JFreemanDaily! As always a great moderator and great chat. Stay well everyone! Miss you all! #lcsm |
| HOJournalClub @HOJournalClub Excited to critically appraise SELECT Trial and ADAURA abstract - adjuvant therapy in EGFR mutated #lcsm #HOJOurnalclub Rules below 👇🏾👇🏾 https://t.co/c2Fz1IMMC1 |
 | Ashley Love Sumrall, MD, FACP @AshleySumrallMD @HOJournalClub @DrMMurphy @DocLHenry @DevikaDasMD @JackWestMD Lurking! Medonc from Charlotte. #lcsm https://t.co/Cictr55BSn |
| Liza Henry McDonald @DocLHenry RT @HOJournalClub: Excited to critically appraise SELECT Trial and ADAURA abstract - adjuvant therapy in EGFR mutated #lcsm #HOJOurnalclub Rules below 👇🏾👇🏾 https://t.co/c2Fz1IMMC1 |
 | Natasha Dhawan, MD @NatashaDhawanMD @HOJournalClub @DrMMurphy @DocLHenry @DevikaDasMD @JackWestMD Hi everyone! I'm Natasha, #palliativecare and soon to be #hemeonc fellow at @DartmouthHitch. Happy to be here! Wasn't able to attend to the #LCSM tweetchat, but hoping some people can join us here! #HOJournalclub #LCSM |
| HOJournalClub @HOJournalClub Let’s dive in right away !!! 🚨🚨🚨 Q1 here and please respond 👇🏾 and use the #lcsm #HOJournalclub https://t.co/9qHLRu0zM1 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: #TargetedTherapy calls for #NGS #LCSM |
| Devika Das, MD, MSHQS @DevikaDasMD @HOJournalClub @DocLHenry @DrMMurphy @JackWestMD A1 Adding some framework for our trainees on critically appraising RCT #hojournalclub #lcsm https://t.co/Qq0iAyurjP |
| H. Jack West, MD @JackWestMD A1) good single arm trial, 2 yr adjuvant erlotinib in EGFR mut+ NSCLC, though including 14% pts w/st 1A NSCLC is questionable. Do they need adjuvant anything? They will def make DFS better just by including many st 1 pts. #HOJOURNALCLUB |
 | Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana @HOJournalClub @DrMMurphy @DocLHenry @DevikaDasMD @JackWestMD Hi! Ana, onc fellow @HemoncUcsf focused on #disparities and thoracic onc #lcsm #HOJournalClub |
| H. Jack West, MD @JackWestMD A1) asked fair Q looking for DFS benefit, but vy little data for benchmark DFS, which will depend greatly on risk of pts enrolled. Still, main Q is just whether results are promising enough to warrant further study. Fine. #HOJOURNALCLUB |
 | Christina Lizaso @btrfly12 RT @JFreemanDaily: Clinical impact of COVID-19 on patients with cancer: Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) (Abs LBA110) #ASCO20 #lcsm https://t.co/t5gL7uphid https://t.co/oGCknRMahw |
 | Glenda Delgado Ramos, MD @GlendaDelgadoR @HOJournalClub @DevikaDasMD @DocLHenry @DrMMurphy @JackWestMD A1 #lcsm #HOJournalclub phase II trial, non-randomized, stage I-III lung cancer post definitive therapy, unblinded, erlotinib therapy for 2y, historical data as control |
 | Aakash Desai, M.B.B.S, M.P.H @ADesaiMD @JackWestMD Can we say DFS is validated as a #surrogate for OS in #LCSM based on this study? https://t.co/rrBUi5evbH |
| HOJournalClub @HOJournalClub Great engagement !! Now to the meat of the study - what were the results of the SELECT Trial ? #lcsm #HOJournalclub https://t.co/jBu4U9Jhq1 |
| HOJournalClub @HOJournalClub @ShoMidha @DevikaDasMD @DocLHenry @DrMMurphy @JackWestMD Does this recurrence post Osi a red flag 🚩 ? #lcsm #HOJournalclub |
| Liza Henry McDonald @DocLHenry @HOJournalClub @DevikaDasMD @DrMMurphy @JackWestMD @JackWestMD any comments on why 2 yrs adj therapy was used in this study design? #HOJournalClub #LCSM |
 | Eric K. Singhi, MD @esinghimd @HOJournalClub @DevikaDasMD @DocLHenry @DrMMurphy @JackWestMD A1. Single arm, open label, phase 2 study. Enrolled resected stage 1A-3A EGFR+ NSCLC s/p adjuvant chemo +/- RT to receive adjuvant erlotinib x 2 yrs. #hojournalclub #lcsm |
#LCSM content from Twitter.